Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00418275
Status:
COMPLETED
Last Update Posted:
2007-01-04
First Post:
2007-01-03
Brief Title:
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke
Sponsor:
Global Biotech
Organization:
Global Biotech
Study Overview
Official Title:
A Dose Finding Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator HTU-PA in Patients With Acute Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke
Detailed Description:
Cerebrovascular disease the third leading cause of death after heart disease and cancer in developed countries has an overall prevalence of 794 per 100000 In the United States it is estimated that more than 400000 patients are discharged each year from hospitals after a stroke The loss of these patients from the work force and the extended hospitalization they require during recovery make serious economic impact In Taiwan Cerebrovascular disease is the second cause of death
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None